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Recently, Helicobacter pylori (H. pylori)-positive peptic ulcer patients were treated by a 
1-week triple therapy [lansoprazole (LPZ) 30 mg, amoxicillin 750 mg and clarithromycin 
200 or 400 mg, each twice daily] without the checking CYP2C19 genotype in Japan. This 
regimen was done to obtain sufficient cure rates for H. pylori infection using a high dose 
of LPZ (60 mg/day) without the great cost of having to determine the genotype.  How-
ever, the failure rate for eradicating H. pylori was reported to be 12.5%.  The reasons for 
this were studied in 33 Japanese patients with H. pylori-positive gastric or duodenal ul-
cer.  Blood samples of the patients were collected to determine the genotype of CYP2C19 
and plasma concentrations of LPZ and its metabolites at 3 h postdose on the morning of 
the 7th day of treatment.  H. pylori infection was cured in 25 of the 33 patients (75.8%). 
The cure rate was highest in the group of poor metabolizers (PM), intermediate in 
the group of extensive metabolizers of the heterozygous type (htEM) and lowest in the 
group of extensive metabolizers of the homozygous type (hmEM).  The relative ratio of 
mean plasma concentration for LPZ among the 3 groups was 1.00:1.43:2.93 (hmEM:
htEM:PM groups).  Our data suggest that success of the eradication is dependent on the 
CYP2C19-related genotypic status or the plasma concentrations of LPZ in a steady state 
condition after a multiple dosing regimen; that is to say, checking CYP2C19 is necessary 
even on occasions when treatment is done by H. pylori eradication methods as performed 
in Japan.  
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The prevalence of Helicobacter pylori (H. pylori) 
infection has increased with age in the Japanese. 
For Japanese born after 1950, the frequency of H. 
pylori infection increased at approximately 1% 
per year; for those born before 1950 the preva-
lence was high (70–80%) and relatively constant 
(Asaka et al., 1992).  H. pylori infection was sig-
nificantly more prevalent in Japanese than in Eu-
ropeans and Americans (Schlemper et al., 1995). 
A high incidence of gastric cancer was reportedly 
related to infection with H. pylori (Parsonnet et 
al., 1991), and the highest incidence rates of gas-
tric cancer in the world are found in Japan (Parkin 
et al., 2001).  A high prevalence of the infec-
tion may portend continued high rates of gastric 
cancer in the forthcoming years (Uemura et al., 
1997). Thus, it is highly important that H. pylori 
be eradicated in Japan.
 There are many reports available regarding 
the predictive factors for successful treatment of 
H. pylori, and several host risk factors as well as 
bacterial factors are known to affect cure rates 
(Fallone et al., 1999; Kamada et al., 1999; Fu-
jioka, 2000; Hoshiya et al., 2000).  One recent 
report suggested that a polymorphism  in the gene 
encoding the CYP2C19 enzyme for the proton 
pomp inhibitor (PPI) metabolism could affect the 
chance for a cure in H. pylori-positive patients 
who were treated with a 2-week dual therapy regi-
men with omeprazole and amoxicillin (Furuta et 
al., 1998).  A recent trend for eradicating H. py-
lori involves the use of PPI-based triple therapies 
(Pounder, 1997; Unge, 1997) in order to obtain 
higher cure rates of eradication, while the impact 
of a CYP2C19 genetic polymorphism on the suc-
cess of eradication in PPI-based triple therapies is 
still unclear.
 Lansoprazole (LPZ) is a substituted benz-
imidazole derivative that effectively inhibits gas-
tric acid secretion by irreversibly binding to the 
proton pump (H+/K+-ATPase) in gastric parietal 
cells (Sachs et al., 1995).  LPZ is metabolized by 
a genetically determined S-mephenytoin 4'-hy-
droxylase [cytochrome P4502C19 (CYP2C19)] 
in the liver (Pearce et al., 1996).  5-Hydroxylan-
soprazole (OH-LPZ) and lansoprazole sulfone 
(LPZ-SFN) are the 2 major metabolites detectable 
in plasma (Pearce et al., 1996).  An interindividu-
al difference in the activity of CYP2C19 has been 
reported in relationship to the metabolic disposi-
tion of LPZ:  in individuals with a poor metabo-
lizer (PM) phenotype of CYP2C19, the area under 
the plasma concentration-time curve of LPZ is 
markedly increased (Sohn et al., 1997; Katsuki et 
al., 1997; Ieiri et al., 2001).  Therefore, acid secre-
tion in PMs of those who are undergoing LPZ 
therapy is assumed to be more strongly inhibited 
than in extensive metabolizers (EMs). The activ-
ity of CYP2C19 depends on CYP2C19 genotype 
status.  Recently, Adachi et al. (2000) reported 
that the acid-inhibitory effect of LPZ was affected 
by CYP2C19 genotype status.  Such studies sug-
gest that the usual dose of LPZ for peptic ulcer (30 
mg a day) may not attain therapeutically sufficient 
acid suppression in subjects who are homozygous 
EMs (hmEMs).  In Japan, H. pylori eradication 
therapy was approved under the Japanese system 
of health insurance in November 2000.  Since 
then, H. pylori-positive peptic ulcer patients were 
treated by a 1-week triple therapy (LPZ 30 mg, 
amoxicillin 750 mg and clarithromycin 200 or 
400 mg, each twice daily) without checking for 
CYP2C19 genotypes in Japan (Satoh, 2002). 
The aim of this new regimen was to obtain high 
plasma concentrations of LPZ and sufficient cure 
rates for H. pylori infection using twice the dose 
of LPZ (60 mg a day) without the great cost for 
determining the genotype.  This regimen showed 
that the H. pylori eradication rate was 87.5% in 
2001 (Asaka et al., 2001); that is to say, the failure 
rate using this regimen for H. pylori eradication 
was 12.5%.  The reasons for the failure have not 
been minutely analyzed so far.  Accordingly, we 
conducted a prospective study in order to exam-
ine the reasons for the 1-week LPZ-based triple 
therapy regimen (LPZ 30 mg, amoxicillin 750 mg 
and clarithromycin 200 or 400 mg, each twice 
daily); for instance, we focused on i) the relation-
ship between the CYP2C19 polymorphism and 
the plasma concentration of LPZ on the last day (= 
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steady state condition) of a 1-week triple therapy, 
ii) the relevancy between the CYP2C19 polymor-
phism and the cure rates of H. pylori infection, 
iii) existence of anti-biotic resistant H. pylori, iv) 





The study samples were collected from 33 Japa-
nese patients with gastric ulcer (n = 18) or duode-
nal ulcer (n = 15), who attended Tottori University 
Hospital or Toyooka Hospital.  Twenty-seven pa-
tients were male and 6 were female; the mean age 
(± SD) was 56.8 ± 11.4 years.  All patients had 
endoscopically proven gastric or duodenal ulcer 
and were positive for H. pylori based on plural 
evidence from rapid urease testing, culture, 13C-
urea breath testing and histologic examination.
 For eradication of H. pylori, all patients re-
ceived a 1-week triple therapy comprising LPZ 
30 mg, amoxycillin 750 mg and clarithromycin 
200 mg, all twice daily with food.  Blood samples 
were collected to determine the genotype of 
CYP2C19 and blood concentrations of LPZ, OH-
LPZ and LPZ-SFN at 3 h postdose on the morn-
ing of the 7th day which was after the beginning 
of drug administration for H. pylori eradication. 
We examined the blood concentrations of LPZ 
and its metabolites at 3 h postdose on the morn-
ing of the 7th day as parameters to estimate LPZ 
pharmacokinetics because the point of blood sam-
pling was in a steady state of LPZ plasma concen-
tration.
 The blood samples were centrifuged and the 
plasma including LPZ and its metabolites were 
immediately collected.  The plasma was stored 
at –20˚C until analysis.  The concentrations of 
LPZ and its metabolites were determined by high 
performance liquid chromatography (Aoki et al., 
1991).  
 Genomic DNA was prepared from blood 
samples using a DNA extractor WB kit (Wako, 
Osaka, Japan).  The genotype CYP2C19 was 
identified using PCR-restriction fragment length 
polymorphism (PCR-RFLP) analysis as previ-
ously described (Ieiri et al., 2001; Kimura et al., 
1998).  
 Patient adherence to therapy and occurrence 
of side effects were assessed by interview.  Gas-
troduodenoscopy and determination of H. pylori 
infection were done before and 1 month after 
treatment.  Endoscopists were uninformed of 
patient treatment status and genotypes.  Written 
informed consent was obtained from each patient 
before the study began and our protocol was ap-
proved by the ethics review board of Tottori Uni-
versity Faculty of Medicine and Toyooka Hospi-
tal.
 The susceptibility of each strain of H. pylori 
for clarithromycin was assessed in our laboratory 
at Tottori University Hospital by determining the 
minimal inhibitory concentration to the drug us-
ing an Etest (Aska Diagnostics, Tokyo, Japan).
 Statistical differences in cure rates for H. 
pylori infection among the 3 genotype groups 
were determined by one-way analysis of variance 
and the Fisher exact test.  Blood concentrations of 
LPZ, OH-LPZ and LPZ-SFN were analyzed for 
statistical differences using an unpaired t-test. A 






No clinically undesirable signs or symptoms at-
tributable to the therapy were noted during the 
entire study period.  All patients completed the 
study according to protocol.  Adherence to the 
prescribed medication regimen was 100% in all 
patients.
 Subjects were genotypically classified into 
the 3 groups on the basis of PCR-RFLP analysis 
for CYP2C19 as shown in Table 1:  homozygous 
EM group (hmEM), heterozygous EM (htEM) 
group and PM group.
 H. pylori infection was cured in 25 of the 
33 patients (75.8%).  The cure rates of H. pylori 
infection for the 3 genotype groups are shown in 
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Table 2.  Cure rates of Helicobacter pylori in-
fection in the 3 genotype groups
 Number of patients Cure rate (%) 
hmEM 11 7/11 (  63.6%)
htEM 16 12/16 (  75.0%)
PM 6  6/ 6 (100.0%)* 
 EM, extensive metabolizer; hmEM, homozygous EM; 
htEM, heterozygous EM; PM, poor metabolizer. 
* P < 0.05 for the PM group compared with the hmEM 
group.
Table 3.  Mean plasma concentrations of LPZ, OH-LPZ and LPZ-SFN on the morning of the last 
day of a 1-week triple therapy
Group      Number of patients     LPZ OH-LPZ      LPZ-SF
hmEM 11 402.4 ± 156.7 31.0 ± 10.5 6.3 ± 4.5
htEM 16 573.7 ± 123.1 24.3 ± 6.4 32.7 ± 11.3
PM  6  1181.0 ± 247.8* 14.5 ± 7.7 99.0 ± 30.5†
 EM, extensive metabolizer; hmEM, homozygous EM; htEM, heterozygous EM; LPZ, lansoprazole; LPZ-SFN, lan-
soprazole sulfone; OH-LPZ, 5-hydroxylansoprazole; PM, poor metabolizer.
 Values are mean ± SEM (ng/mL).  
* P < 0.05 for the PM group compared with the hmEM or htEM group.
† P < 0.05 for the PM group compared with the hmEM or htEM group.
Table 1.  Demographic and clinical characteris-
tics of 33 patients with peptic ulcer in the 3 geno-
type groups
    Variable  hmEM htEM PM
  [11] [16] [6]
CYP2C19 status  wt/wt wt/m1† or m1/m1‡ or
  wt/m2†† m1/m2‡‡
 EM, extensive metabolizer; hmEM, homozygous EM; 
htEM, heterozygous EM; PM, poor metabolizer; m1, 
CYP2C19 polymorphism in exon 5; m2, CYP2C19 poly-
morphism in exon 4; wt, wild-type.
 [   ], number of patients.
 † Heterozygous for CYP2C19m1 without CYP2C19m2.
†† Heterozygous for CYP2C19m2 without CYP2C19m1.
 ‡ Homozygous for CYP2C19m1 without CYP2C19m2.
‡‡ Heterozygous for both CYP2C19m1 and CYP2C19m2.
Table 2.  The cure rate was the highest in the PM 
group, intermediate in the htEM group and the 
lowest in the hmEM group.  The cure rate of the 
PM group was significantly higher than that of the 
hmEM group (P < 0.05).  
 The mean plasma concentrations of LPZ 
and its metabolites in relation to the 3 genotype 
groups are summarized in Table 3.  These plasma 
concentrations (Table 3) were measured on the 
morning of the last day of therapy.  An intergeno-
typic difference was observed for LPZ, OH-LPZ 
and LPZ-SFN described as follows:  the relative 
ratio of mean plasma concentration for LPZ was 
1.00:1.43:2.93 (hmEM:htEM:PM groups); the 
mean concentration of LPZ in the PM group was 
significantly higher than that in the hmEM or 
htEM group (P < 0.05); the relative ratio of mean 
plasma concentration was 1.00:0.78:0.47 for OH-
LPZ and 1.00:5.19:15.71 for LPZ-SFN (hmEM: 
htEM:PM groups, respectively); and the mean 
concentration of LPZ-SFN in the PM group was 
significantly higher than that in the hmEM or 
htEM group (P < 0.05).
 
Cases in which eradication of H. pylori failed
 
Four patients (Patients 1 to 4) failed to be cured 
in the hmEM group (Table 4).  Among the 4 
patients, all strains of H. pylori were antibiotic-
sensitive but the levels of plasma concentration 
of LPZ were not enough to eradicate H. pylori. 
Because the uptake of clarithromycin (CAM) into 
gastric tissue was enhanced in the case of a high-
pH environment, keeping the intragastric pH at 
neutral levels by using acid-inhibitory agents such 
as LPZ may increase the availability of active an-
tibiotics (Endo et al., 2001a, 2001b).  So hmEMs 
are impeded in the eradication of H. pylori.  Four 
patients (Patients 5 to 8) failed to be cured in the 
35
H. p. eradication by Japanese regimen
Table 4.  Antibiotics-sensitive status of H. pylori and plasma concentrations of LPZ, OH-LPZ and LPZ-
SFN on the morning of the last day of a 1-week triple therapy in cases failured for H. pylori eradication
  Patient  Plasma concentration (ng/mL)  Susceptibility
Group  number LPZ OH-LPZ LPZ-SFN Sensitive/resistant
hmEM 1   28 < 10 < 10 Sensitive
 2  149   24 < 10 Sensitive
 3  366   23 < 10 Sensitive
 4   84   21 < 10 Sensitive
htEM 5  807   53 < 10 Resistant
 6  636   69   40 Resistant
 7† 1107 < 10  150 Sensitive
 8   69 < 10 < 10 Sensitive
PM All cases of PM were successful for H. pylori eradication.  
  Mean plasma concentration of LPZ in the PM group was 1181.0 ng/mL as shown in Table 3.
 EM, extensive metabolizer; hmEM, homozygous EM; htEM, heterozygous EM; LPZ, lansoprazole; LPZ-SFN, lan-
soprazole sulfone; OH-LPZ, 5-hydroxylansoprazole; PM, poor metabolizer.
† Patient 7 had an unusual status of treatment for H. pylori eradication as shown in text.
htEM group (Table 4).  The strains of H. pylori 
were antibiotic (CAM)-resistant in 2 (Patients 5 
and 6) of the 4.  The strain of H. pylori was an-
tibiotic (CAM)-sensitive, but the level of plasma 
concentration of LPZ was not enough to eradicate 
H. pylori in 1 (Patient 8) of the 4.
 Patient 7 (Table 4) had the following sta-
tus for treatment of H. pylori eradication:  i) 62 
year old male, ii) drug compliance was good, iii) 
strain of H. pylori was antibiotic-sensitive, iv) no 
other disease except for peptic ulcer and v) level 
of concentration of LPZ was enough to eradicate 
H. pylori.  This patient had treatment for H. py-
lori eradication twice. The 1st time was with the 
1-week triple therapy (LPZ 30 mg, amoxicillin 
750 mg and clarithromycin 200 mg, each twice 
daily) and the 2nd time was another 1-week triple 
therapy regimen (LPZ 30 mg, amoxicillin 750 
mg and clarithromycin 400 mg, each twice daily). 
Neither method could produce any successful H. 
pylori eradication.  On the other hand, all cases in 





Katsuki et al. (1997) have already reported on the 
relationship between CYP2C19 genotype status 
and metabolic disposition of LPZ using the single 
oral dose method (single oral administration of 
30 mg LPZ) in Japanese subjects, and have shown 
that the hydroxylation of LPZ to OH-LPZ was ap-
parently impaired in the PM.  However, reports 
describing the relationship between CYP2C19 
genotype status and metabolic disposition of LPZ 
using a multiple-dosing regimen are rare.  In 
2001, we planned a study using young healthy vol-
unteers who were negative for H. pylori infection 
to provide preliminary information that should be 
considered when prescribing LPZ in a multiple-
dose manner with reference to the CYP2C19-
related genotype status (Ieiri et al., 2001). The 
healthy volunteers received 30 mg doses of LPZ 
once daily for 8 days and their pharmacokinetic 
parameters were measured using blood samples 
which were collected on the 8th day.  The results 
showed that the relative ratio of the maximal 
concentration (Cmax) of LPZ was 1.00:1.29:2.00, 
that of OH-LPZ 1.00:1.20:0.20 and that of LPZ-
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SFN 1.00:1.00:5.00 (hmEM:htEM:PM groups, 
respectively) on the 8th day.  These data indicate 
the statistical differences of Cmax between any 
2 genotypic groups among the 3 groups were not 
significant for LPZ; however, the differences of 
Cmax between the non-PM (hmEM and htEM) 
and PM groups were significant for OH-LPZ and 
LPZ-SFN (P < 0.001) (Ieiri et al., 2001).
 In the present study, we observed the plasma 
concentration on the last day of a 1-week triple 
therapy for H. pylori eradication.  The mean lev-
els of plasma LPZ and LPZ-SFN in the PM group 
were significantly higher than those in the hmEM 
or htEM group after the multiple-dosing regimen. 
The relative ratio of mean plasma concentra-
tion was 1.00:1.43:2.93 for LPZ; 1.00:0.78:0.47 
for OH-LPZ and 1.00:5.19:15.71 for LPZ-SFN 
(hmEM:htEM:PM groups, respectively).  These 
differences of relative ratio on the 3 genotypic sta-
tus after a multiple-dose regimen are clearer than 
those of our previous preliminary study using 30 
mg doses of LPZ once a day for 8 days (Ieiri et 
al., 2001).
 These differences in the 3 genotypic status 
which influence the plasma concentration of LPZ 
after a multiple-dose regimen are important, 
because the cure rates of H. pylori infection are 
different according to CYP2C19 genotype status 
as shown in Table 2.  In Japan, H. pylori-positive 
peptic ulcer patients were treated with a 1-week 
triple therapy (LPZ 30 mg, amoxicillin 750 mg 
and clarithromycin 200 or 400 mg, each twice 
daily) without checking for the CYP2C19 geno-
type.  The aim of this method was to obtain high 
plasma concentrations of LPZ and sufficient cure 
rates for H. pylori infection using two doses of 
LPZ (60 mg a day) without the great cost of deter-
mining the genotype.  In this method, high eradi-
cation rates (84–91%) for H. pylori infection were 
found in gastroduodenal ulcer patients (Satoh, 
2002).  However, our data suggest that checking 
CYP2C19 is necessary even on the occasion of 
treatment by H. pylori eradication as it is done 
in Japan. The cure rate was highest (100.0%) in 
the PM group, intermediate (75.0%) in the htEM 
group and lowest (63.6%) in the hmEM group 
in the present study (Table 2); our data meant 
that the success of eradication was dependent on 
CYP2C19-related genotypic status or mean plas-
ma concentrations of LPZ in a steady state condi-
tion, which is the morning of the last day on the 
1-week triple therapy.  In Japan, the prevalence of 
CAM-resistant H. pylori strains is about 10% to 
20% (Satoh, 2002).  Miki et al. (2003) reported 
that the key to successful eradication of H. pylori, 
using LPZ with CAM and amoxicillin, is CAM 
susceptibility, and not a CYP2C19 polymorphism. 
However, our results mentioned above indicate 
that not only administration of special antibiotics 
(for example, metronidazole) against CAM-resis-
tant H. pylori strain but also CYP2C19-related 
genotypic status should be considered as a coun-
termeasure in the failure of H. pylori eradication. 
Under the Japanese regimen for H. pylori eradica-
tion, we suggest that CYP2C19 genotyping should 
be done when H. pylori eradication fails, and then 
an adequate dose of LPZ should be administered 
to the patients; in addition to these treatments, 
checking the resistance ability of H. pylori against 
antibiotics is also important.  
 By the way, we experienced one case in 
which eradication of H. pylori failed notwith-
standing the high level of plasma LPZ concen-
tration, as in the PM group and antibiotic-sensi-
tivity of the H. pylori strain (Patient 7 in Table 
4).  Wermeille et al. (2002) reported that poor 
compliance and bacterial resistance could only 
explain 40% of the failures in H. pylori eradica-
tion.  Their report suggests that other factors must 
be involved.  LPZ is known to be metabolized 
via CYP3A4 as well as CYP2C-19 (Pearce et al., 
1996; Ishizaki and Horai, 1999).  So CYP3A4 
allelic variants may have been involved in the 
failure of the eradication in Patient 7 (Table 4). 
Several recent studies have reported that CYP3A4 
allelic variants exist in Caucasian and African-
American populations (Paris et al., 1999; Sata et 
al., 2000; van Schaik et al., 2000; Wandel et al., 
2000). However, whether these isoform variants 
are associated with the altered metabolism of LPZ 
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appears to be controversial and conflicting (Sata 
et al., 2000; Wandel et al., 2000).  Because the 
existence of CYP3A4-related PMs has not been 
reported in any part of the Japanese population so 
far, we did not examine CYP3A4-related pheno-
typing/genotyping factor(s) in the present study. 
On the other hand, there is also the possibility that 
other factors such as drug absorption or biological 
drug delivery/distribution may sometimes affect 
treatment success. Further examination is needed 
on these cases.
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